Orchestra BioMed Holdings (OBIO) Stock Forecast: StockMap's 2-Week Call
OBIO stock forecast: StockMap's model makes no two-week call on Orchestra BioMed Holdings after the Nov 19 close: its evidence is split, 7 reasons for and 8 against. Right in 3 of 4 two-week windows on OBIO since Aug 21; by chance, a call on the same dates was right 71% of the time.
Orchestra BioMed Holdings last closed at $7.00, -6.17% on the session.
Against the IVW growth benchmark the position is -3.84% over the forecast window.
Orchestra BioMed Holdings' market cap is $550.91M as of November 19, 2026.
No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is 10 (too close to call).
Where OBIO sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 7 bullish and 8 bearish.
Agreement across those insights is 47%.
13 daily calls for OBIO so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Orchestra BioMed Holdings in the 5th percentile on return on equity, where 100 is best.
Orchestra BioMed Holdings is classified under Health Care / Health Care Equipment & Supplies.
StockMap tracks Orchestra BioMed Holdings as the 72nd largest of the 141 companies it covers in the Health Care Equipment & Supplies industry, part of the Health Care sector.
Across that group the current two-week reads are 69 Neutral, 55 Moderate Underperform, 14 Strong Underperform and 3 Moderate Outperform.
On that composite Orchestra BioMed Holdings ranks 9th of 141 in the group, against a group median of -0.18.